Nuvalent Inc - Class A — Quarterly Financial Data (NASDAQ:NUVL) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics Dividends

Quarterly Annual

Dividends per share —————— — Dividend yield % —————— — Payout ratio % —————— —

뉴스

Nuvalent 4. çeyrek zararını açıkladı, akciğer kanseri ilacı için FDA kararını bekliyor

Nuvalent reports Q4 loss, awaits FDA decision on lung cancer drug

Drugmakers turn to AI to speed trials, regulatory submissions

Nuvalent Inc hissesi 112,89 dolar ile 52 haftalık zirveyi gördü

Nuvalent Inc stock hits 52-week high at 112.89 USD

FDA, Nuvalent’in ROS1 pozitif KHDAK tedavisi için NDA başvurusunu kabul etti

FDA accepts Nuvalent’s NDA for ROS1-positive NSCLC treatment

Nuvalent (NUVL) chief legal officer Miller sells $676k in stock

Nuvalent CSO Pelish sells shares worth $501,752

Nuvalent (NUVL) chief development officer sells $721k in stock

What's Going On With Royalty Pharma Stock Wednesday? - Royalty Pharma (NASDAQ:RPRX)

3 Biotech Stocks With Major 2026 Catalysts